Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 7;10:11188. doi: 10.1038/s41598-020-67702-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of EA treatments on visceral hypersensitivity, measured by electromyography (EMG) of abdominal muscles’ visceromotor responses (VMR) to colorectal distension pressure (CRD) (Mean ± SD, n = 6). The EMG and mechanical irritation signals were quantified using the MedLab U/4C501 software (Nanjing Medease Science and Technology Co., Ltd, China, https://www.medease.com.cn). EMG activities during distensions minus resting activities were considered as VMRs to CRD, and are expressed as millivoltage per-second (mV/s). The VMRs were increased with higher CRD pressures (a–f). VH or EA group versus Control group (P < 0.05; ANOVA P = 0.016) on day 7; Sham-A or VH or EA group (P < 0.01, 0.05) versus Control group with 40–100 mmHg (ANOVA P = 0.000) at days 7–22; Sham-A or VH group (P < 0.01) versus Control group with 20 mmHg on day 10 (ANOVA P = 0.001) and 13–22 (ANOVA P = 0.000).; Sham-A or VH group (P < 0.01) versus EA group with 80–100 mmHg (ANOVA P = 0.000) on day 10; Sham-A or VH group versus EA group (P < 0.01, 0.05) with 40–100 mmHg (ANOVA P = 0.000) on day 13; Sham-A or VH group versus EA group (P < 0.01, 0.01) with 20–100 mmHg at days 16–22. **P < 0.01, *P < 0.05, VH/ Sham-A/EA group versus Control group. ⁺⁺P < 0.01 and ⁺P < 0.05, Sham-A group versus EA group; ^##P < 0.01, ^#P < 0.05, VH group versus EA group. One-way ANOVA followed by Bonferroni’s post-hoc test.